SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jocelyne Ventre-Dominey, Hélène Mollion, Stephane Thobois, Emmanuel Broussolle, Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease, Behavioural Brain Research, 2016, 302, 131

    CrossRef

  2. 2
    Ilona Csoti, Wolfgang H. Jost, Heinz Reichmann, Parkinson’s disease between internal medicine and neurology, Journal of Neural Transmission, 2016, 123, 1, 3

    CrossRef

  3. 3
    O. Băjenaru, A. Ene, B. O. Popescu, J. A. Szász, M. Sabău, D. F. Mureşan, L. Perju-Dumbrava, C. D. Popescu, A. Constantinescu, I. Buraga, M. Simu, The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience, Journal of Neural Transmission, 2016, 123, 4, 407

    CrossRef

  4. 4
    Mary Buckley, Desmond O'Neill, Ageism in Studies of Rehabilitation in Parkinson's Disease, Journal of the American Geriatrics Society, 2015, 63, 7
  5. 5
    Jan-Peer Elshoff, Willi Cawello, Jens-Otto Andreas, Francois-Xavier Mathy, Marina Braun, An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome, Drugs, 2015, 75, 5, 487

    CrossRef

  6. 6
    Shang-Ming Chiou, Yu-Chin Lin, Ming-Kuei Lu, Chon-Haw Tsai, Bilateral subthalamic stimulation for advanced Parkinson disease: early experience at an Eastern center, Neurological Sciences, 2015, 36, 4, 515

    CrossRef

  7. 7
    Amit Khairnar, Peter Latta, Eva Drazanova, Jana Ruda-Kucerova, Nikoletta Szabó, Anas Arab, Birgit Hutter-Paier, Daniel Havas, Manfred Windisch, Alexandra Sulcova, Zenon Starcuk, Irena Rektorova, Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson’s Disease: A Pilot Study, Neurotoxicity Research, 2015, 28, 4, 281

    CrossRef

  8. 8
    Pantelis Stathis, Spiridon Konitsiotis, Angelo Antonini, Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias, Expert Review of Neurotherapeutics, 2015, 15, 2, 207

    CrossRef

  9. 9
    Christine R. Swanson, Yosef Berlyand, Sharon X. Xie, Roy N. Alcalay, Lama M. Chahine, Alice S. Chen-Plotkin, Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients, Movement Disorders, 2015, 30, 12
  10. 10
    Michel Engeln, Philippe De Deurwaerdère, Qin Li, Erwan Bezard, Pierre-Olivier Fernagut, Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia, Cerebral Cortex, 2015, 25, 9, 2783

    CrossRef

  11. 11
    Danhui Zhang, Tanuja Bordia, Matthew McGregor, J. Michael McIntosh, Michael W. Decker, Maryka Quik, ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease, Movement Disorders, 2014, 29, 4
  12. 12
    Annalisa Pinna, Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued, CNS Drugs, 2014, 28, 5, 455

    CrossRef

  13. 13
    R. L. M. Jansen, B. Brogan, A. J. Whitworth, E. J. Okello, Effects of Five Ayurvedic Herbs on Locomotor Behaviour in a Drosophila melanogaster Parkinson's Disease Model, Phytotherapy Research, 2014, 28, 12
  14. 14
    Olivier Rascol, Jejunal levodopa infusion in Parkinson's disease, The Lancet Neurology, 2014, 13, 2, 128

    CrossRef

  15. 15
    Jordi Bonaventura, Alberto J. Rico, Estefanía Moreno, Salvador Sierra, Marta Sánchez, Natasha Luquin, Daniel Farré, Christa E. Müller, Eva Martínez-Pinilla, Antoni Cortés, Josefa Mallol, Marie-Therese Armentero, Annalisa Pinna, Enric I. Canela, Carme Lluís, Peter J. McCormick, José L. Lanciego, Vicent Casadó, Rafael Franco, l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus, Neuropharmacology, 2014, 79, 90

    CrossRef

  16. 16
    A. Todorova, P. Jenner, K. Ray Chaudhuri, Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected, Practical Neurology, 2014, 14, 5, 310

    CrossRef

  17. 17
    Uli Hacksell, Ethan S. Burstein, Krista McFarland, Roger G. Mills, Hilde Williams, On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis, Neurochemical Research, 2014, 39, 10, 2008

    CrossRef

  18. 18
    Lynda Peterson, Kathleen P. Ismond, Elisha Chapman, Patrick Flood, Potential Benefits of Therapeutic Use of β2-Adrenergic Receptor Agonists in Neuroprotection and Parkinson’s Disease, Journal of Immunology Research, 2014, 2014, 1

    CrossRef

  19. 19
    Taku HATANO, Akito HAYASHI, Nobutaka HATTORI, Therapeutic Strategy for Parkinson^|^#39;s Disease, The Japanese Journal of Rehabilitation Medicine, 2014, 51, 11, 700

    CrossRef

  20. 20
    P. Cesaro, L. Defebvre, Traitement médicamenteux de la maladie de Parkinson à la phase précoce (de novo et « lune de miel »), Revue Neurologique, 2014, 170, 4, 237

    CrossRef

  21. 21
    Alice S. Chen-Plotkin, Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases, Neuron, 2014, 84, 3, 594

    CrossRef

  22. 22
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  23. 23
    K.A. Jellinger, Pathobiology of Human Disease, 2014,

    CrossRef

  24. 24
    Masahiko Tomiyama, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  25. 25
    Sreedevi Chandrasekaran, Danail Bonchev, A NETWORK VIEW ON PARKINSON'S DISEASE, Computational and Structural Biotechnology Journal, 2013, 7, 8, 1

    CrossRef

  26. 26
    Owen A. Ross, A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease, Current Genetic Medicine Reports, 2013, 1, 1, 52

    CrossRef

  27. 27
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  28. 28
    Mee-Sook Song, Dmitriy Matveychuk, Erin M. MacKenzie, Maryana Duchcherer, Darrell D. Mousseau, Glen B. Baker, An update on amine oxidase inhibitors: Multifaceted drugs, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 118

    CrossRef

  29. 29
    Jin-Feng Li, Hong-Lei Yin, Adam Shuboy, Hai-Feng Duan, Ji-Yu Lou, Jing Li, Hong-wei Wang, Yun-Liang Wang, Differentiation of hUC-MSC into dopaminergic-like cells after transduction with hepatocyte growth factor, Molecular and Cellular Biochemistry, 2013, 381, 1-2, 183

    CrossRef

  30. 30
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  31. 31
    E Mazzio, S Deiab, K Park, KFA Soliman, High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors, Phytotherapy Research, 2013, 27, 6
  32. 32
    Aimen Kasasbeh, Osama A. Abulseoud, Joseph Y. Matsumoto, Squire M. Stead, Stephan J. Goerss, Bryan T. Klassen, John Huston, Hoon-Ki Min, Kendall H. Lee, Mark A. Frye, Lack of differential motor outcome with subthalamic nucleus region stimulation in Parkinson’s disease, Journal of Clinical Neuroscience, 2013, 20, 11, 1520

    CrossRef

  33. 33
    Jeffrey R. Liddell, Daniel Obando, Joe Liu, George Ganio, Irene Volitakis, Su San Mok, Peter J. Crouch, Anthony R. White, Rachel Codd, Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease, Free Radical Biology and Medicine, 2013, 60, 147

    CrossRef

  34. 34
    Johan Lökk, Seyed-Mohammad Fereshtehnejad, Managing palliative care in Parkinson’s disease from diagnosis to end-stage disease: what the clinician should know, Neurodegenerative Disease Management, 2013, 3, 2, 169

    CrossRef

  35. 35
    Maryka Quik, Carla Campos, Sharon R. Grady, Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: Studies with parkinsonian nicotinic receptor knockout mice, Biochemical Pharmacology, 2013, 86, 8, 1153

    CrossRef

  36. 36
    Maryka Quik, Archana Mallela, Jason Ly, Danhui Zhang, Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease, Movement Disorders, 2013, 28, 10
  37. 37
    Maryka Quik, Archana Mallela, Matthew Chin, J. Michael McIntosh, Xiomara A. Perez, Tanuja Bordia, Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function, Neurobiology of Disease, 2013, 50, 30

    CrossRef

  38. 38
    Achim Schneeberger, Alexandra Kutzelnigg, Markus Mandler, Parkinson’s disease vaccine: clinical trial challenges when striving for disease modification, Clinical Investigation, 2013, 3, 1, 1

    CrossRef

  39. 39
    Olivier Rascol, Physical exercise in Parkinson disease: Moving toward more robust evidence?, Movement Disorders, 2013, 28, 9
  40. 40
    M. Zibetti, M. Rizzone, A. Merola, S. Angrisano, L. Rizzi, E. Montanaro, A. Cicolin, L. Lopiano, Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease, Acta Neurologica Scandinavica, 2013, 127, 5
  41. 41
    Dénes Zádori, Levente Szalárdy, József Toldi, Ferenc Fülöp, Péter Klivényi, László Vécsei, Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease, Journal of Neural Transmission, 2013, 120, 4, 673

    CrossRef

  42. 42
    Jingwei Tian, Guangying Du, Liang Ye, Xin Yu, Jianzhao Zhang, Hongbo Wang, Pengfei Yu, Fenghua Fu, Wanhui Liu, Youxin Li, Xiaobo Cen, Xiaolin Guan, Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys, Food and Chemical Toxicology, 2013, 52, 143

    CrossRef

  43. 43
    Liang Ye, Xiaolin Guan, Jingwei Tian, Jianzhao Zhang, Guangying Du, Xin Yu, Pengfei Yu, Xiaobo Cen, Wanhui Liu, Youxin Li, Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats, Food and Chemical Toxicology, 2013, 56, 81

    CrossRef

  44. 44
    Maryka Quik, Carla Campos, Tanuja Bordia, Jon-Paul Strachan, Jenny Zhang, J. Michael McIntosh, Sharon Letchworth, Kristen Jordan, α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats, Neuropharmacology, 2013, 71, 191

    CrossRef

  45. 45
    Jiro Kasahara, Mohammed Emamussalehin Choudhury, Hironori Yokoyama, Naoto Kadoguchi, Masahiro Nomoto, Animal Models for the Study of Human Disease, 2013,

    CrossRef

  46. 46
    Christopher J.R. Dunning, Juan F. Reyes, Jennifer A. Steiner, Patrik Brundin, Can Parkinson's disease pathology be propagated from one neuron to another?, Progress in Neurobiology, 2012, 97, 2, 205

    CrossRef

  47. 47
    Tiziana Alberio, Agnese C. Pippione, Cristoforo Comi, Simone Olgiati, Daniela Cecconi, Maurizio Zibetti, Leonardo Lopiano, Mauro Fasano, Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease, IUBMB Life, 2012, 64, 10
  48. 48
    Sarah Vercruysse, Hannes Devos, Liesbeth Munks, Joke Spildooren, Jochen Vandenbossche, Wim Vandenberghe, Alice Nieuwboer, Elke Heremans, Explaining freezing of gait in Parkinson's disease: Motor and cognitive determinants, Movement Disorders, 2012, 27, 13
  49. 49
    Joseph H Friedman, Management of psychotic symptoms in Parkinson’s disease, Clinical Practice, 2012, 9, 1, 49

    CrossRef

  50. 50
    Maryka Quik, Xiomara A. Perez, Tanuja Bordia, Nicotine as a potential neuroprotective agent for Parkinson's disease, Movement Disorders, 2012, 27, 8
  51. 51
    Helge Müller, Frauke Knossalla, Lorenz Breuer, Johannes Kornhuber, Lars Marquardt, Nude Photography: Abuse, Obsession, Delusion, and Finally Depression, The American Journal of Medicine, 2012, 125, 8, e3

    CrossRef

  52. 52
    Linnea R. Freeman, Jeffrey N. Keller, Oxidative stress and cerebral endothelial cells: Regulation of the blood–brain-barrier and antioxidant based interventions, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012, 1822, 5, 822

    CrossRef

  53. 53
    Arif Dalvi, Parkinsonism, Disease-a-Month, 2012, 58, 12, 690

    CrossRef

  54. 54
    Santiago Perez-Lloret, María Verónica Rey, Nelly Fabre, Fabienne Ory, Umberto Spampinato, Christine Brefel-Courbon, Jean-Louis Montastruc, Olivier Rascol, Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease, Clinical Neuropharmacology, 2012, 35, 6, 261

    CrossRef

  55. 55
    Gulsen Babacan-Yildiz, Esra Gursoy, Mehmet Kolukisa, Arif Celebi, Restless Legs Syndrome Responsive to Rasagiline Treatment, Clinical Neuropharmacology, 2012, 35, 2, 88

    CrossRef

  56. 56
    Maryka Quik, Keon Min Park, Maya Hrachova, Archana Mallela, Luping Z. Huang, J. Michael McIntosh, Sharon R. Grady, Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice, Neuropharmacology, 2012, 63, 3, 450

    CrossRef

  57. 57
    Perdita A. Cheshire, David R. Williams, Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease, Journal of Clinical Neuroscience, 2012, 19, 3, 343

    CrossRef

  58. 58
    J. Blesa, C. Pifl, M.A. Sánchez-González, C. Juri, M.A. García-Cabezas, R. Adánez, E. Iglesias, M. Collantes, I. Peñuelas, J.J. Sánchez-Hernández, M.C. Rodríguez-Oroz, C. Avendaño, O. Hornykiewicz, C. Cavada, J.A. Obeso, The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical study, Neurobiology of Disease, 2012, 48, 1, 79

    CrossRef

  59. 59
    Joseph Jankovic, Werner Poewe, Therapies in Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 433

    CrossRef

  60. 60
    Jessica AL Hutter-Saunders, Rodney Lee Mosley, Howard E Gendelman, Pathways towards an effective immunotherapy for Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 12, 1703

    CrossRef